Matching‐Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second‐Line Myelofibrosis Therapy

Hematological Oncology · Published 2026-07-29 · DOI 10.1002/hon.70230

Free full text

Authors (24)

Yi Zhang, Hu Zhou, Qike Zhang, Qingchi Liu, Sujun Gao, Zhijian Xiao, Minghui Duan, Liangming Ma, Wei Wang, Huibing Dang, Guang-sheng He, Hongmei Jing, Junmin Li, Haiping Yang, Huanling Zhu, Chunkang Chang, Yuqing Chen, Xin Du, Mei Hong, Xin Li, Jishi Wang, Na Xu, Shanshan Suo, Jie Jin

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Zhang, Y., Zhou, H., Zhang, Q., et al. (2026). Matching‐Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second‐Line Myelofibrosis Therapy. Hematological Oncology. https://doi.org/10.1002/hon.70230

Related articles